(Boursier.com) — Sensorion enrolled the first patient in its Phase 2a proof-of-concept clinical trial of SENS-401 (Arazasetron) in patients with cisplatin-induced ototoxicity.
Cisplatin and other platinum derivatives are essential chemotherapeutic agents for the treatment of many cancers. Platinum therapies cause permanent and irreversible ototoxicity or hearing loss in approximately 50-60% of adult patients and 90% of pediatric patients who survive cancer. This indication represents a very significant unmet medical need for patients and a large potential market with more than 500,000 patients concerned in the United States, the European Union and Japan.
The trial will analyze a number of secondary endpoints including rate and severity of ototoxicity, change in pure tone PTA (dB) audiometry throughout the study, and safety.
Sensorion expects the publication of interim results during the first half of 2023.
©2023 Boursier.com